Literature DB >> 33104846

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020.

Cristiano Spada1,2, Cesare Hassan3, Davide Bellini4, David Burling5, Giovanni Cappello6, Cristina Carretero7, Evelien Dekker8, Rami Eliakim9, Margriet de Haan10, Michal F Kaminski11, Anastasios Koulaouzidis12, Andrea Laghi13, Philippe Lefere14, Thomas Mang15, Sebastian Manuel Milluzzo16,17, Martina Morrin18, Deirdre McNamara19, Emanuele Neri20, Silvia Pecere17, Mathieu Pioche21, Andrew Plumb22, Emanuele Rondonotti23, Manon Cw Spaander24, Stuart Taylor22, Ignacio Fernandez-Urien25, Jeanin E van Hooft26, Jaap Stoker27, Daniele Regge6,28.   

Abstract

MAIN RECOMMENDATIONS: 1. ESGE/ESGAR recommend computed tomographic colonography (CTC) as the radiological examination of choice for the diagnosis of colorectal neoplasia. Strong recommendation, high quality evidence. ESGE/ESGAR do not recommend barium enema in this setting. Strong recommendation, high quality evidence.2. ESGE/ESGAR recommend CTC, preferably the same or next day, if colonoscopy is incomplete. The timing depends on an interdisciplinary decision including endoscopic and radiological factors. Strong recommendation, low quality evidence. ESGE/ESGAR suggests that, in centers with expertise in and availability of colon capsule endoscopy (CCE), CCE preferably the same or the next day may be considered if colonoscopy is incomplete. Weak recommendation, low quality evidence.3. When colonoscopy is contraindicated or not possible, ESGE/ESGAR recommend CTC as an acceptable and equally sensitive alternative for patients with alarm symptoms. Strong recommendation, high quality evidence. Because of lack of direct evidence, ESGE/ESGAR do not recommend CCE in this situation. Very low quality evidence. ESGE/ESGAR recommend CTC as an acceptable alternative to colonoscopy for patients with non-alarm symptoms. Strong recommendation, high quality evidence. In centers with availability, ESGE/ESGAR suggests that CCE may be considered in patients with non-alarm symptoms. Weak recommendation, low quality evidence.4. Where there is no organized fecal immunochemical test (FIT)-based population colorectal screening program, ESGE/ESGAR recommend CTC as an option for colorectal cancer screening, providing the screenee is adequately informed about test characteristics, benefits, and risks, and depending on local service- and patient-related factors. Strong recommendation, high quality evidence. ESGE/ESGAR do not suggest CCE as a first-line screening test for colorectal cancer. Weak recommendation, low quality evidence.5. ESGE/ESGAR recommend CTC in the case of a positive fecal occult blood test (FOBT) or FIT with incomplete or unfeasible colonoscopy, within organized population screening programs. Strong recommendation, moderate quality evidence. ESGE/ESGAR also suggest the use of CCE in this setting based on availability. Weak recommendation, moderate quality evidence.6. ESGE/ESGAR suggest CTC with intravenous contrast medium injection for surveillance after curative-intent resection of colorectal cancer only in patients in whom colonoscopy is contraindicated or unfeasible. Weak recommendation, low quality evidence. There is insufficient evidence to recommend CCE in this setting. Very low quality evidence.7. ESGE/ESGAR suggest CTC in patients with high risk polyps undergoing surveillance after polypectomy only when colonoscopy is unfeasible. Weak recommendation, low quality evidence. There is insufficient evidence to recommend CCE in post-polypectomy surveillance. Very low quality evidence.8. ESGE/ESGAR recommend against CTC in patients with acute colonic inflammation and in those who have recently undergone colorectal surgery, pending a multidisciplinary evaluation. Strong recommendation, low quality evidence.9. ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least one polyp ≥6 mm detected at CTC or CCE. Follow-up CTC may be clinically considered for 6-9-mm CTC-detected lesions if patients do not undergo polypectomy because of patient choice, comorbidity, and/or low risk profile for advanced neoplasia. Strong recommendation, moderate quality evidence. Source and scope This is an update of the 2014-15 Guideline of the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). It addresses the clinical indications for the use of imaging alternatives to standard colonoscopy. A targeted literature search was performed to evaluate the evidence supporting the use of computed tomographic colonography (CTC) or colon capsule endoscopy (CCE). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendations and the quality of evidence.

Entities:  

Mesh:

Year:  2021        PMID: 33104846     DOI: 10.1007/s00330-020-07413-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  105 in total

1.  Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy.

Authors:  Hermann Brenner; Jenny Chang-Claude; Lina Jansen; Phillip Knebel; Christian Stock; Michael Hoffmeister
Journal:  Gastroenterology       Date:  2013-09-05       Impact factor: 22.682

2.  Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study.

Authors:  R Eliakim; Z Fireman; I M Gralnek; K Yassin; M Waterman; Y Kopelman; J Lachter; B Koslowsky; S N Adler
Journal:  Endoscopy       Date:  2006-10       Impact factor: 10.093

Review 3.  Participation in colorectal cancer screening trials after first-time invitation: a systematic review.

Authors:  C Khalid-de Bakker; D Jonkers; K Smits; I Mesters; A Masclee; R Stockbrügger
Journal:  Endoscopy       Date:  2011-12-01       Impact factor: 10.093

Review 4.  Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas K Rex; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; Theodore R Levin; David Lieberman; Douglas J Robertson
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

5.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths.

Authors:  Ann G Zauber; Sidney J Winawer; Michael J O'Brien; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Benjamin F Hankey; Weiji Shi; John H Bond; Melvin Schapiro; Joel F Panish; Edward T Stewart; Jerome D Waye
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study.

Authors:  Chyke A Doubeni; Sheila Weinmann; Kenneth Adams; Aruna Kamineni; Diana S M Buist; Arlene S Ash; Carolyn M Rutter; V Paul Doria-Rose; Douglas A Corley; Robert T Greenlee; Jessica Chubak; Andrew Williams; Aimee R Kroll-Desrosiers; Eric Johnson; Joseph Webster; Kathryn Richert-Boe; Theodore R Levin; Robert H Fletcher; Noel S Weiss
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391

7.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline.

Authors:  Cristiano Spada; Jaap Stoker; Onofre Alarcon; Federico Barbaro; Davide Bellini; Michael Bretthauer; Margriet C De Haan; Jean-Marc Dumonceau; Monika Ferlitsch; Steve Halligan; Emma Helbren; Mikael Hellstrom; Ernst J Kuipers; Philippe Lefere; Thomas Mang; Emanuele Neri; Lucio Petruzziello; Andrew Plumb; Daniele Regge; Stuart A Taylor; Cesare Hassan; Andrea Laghi
Journal:  Eur Radiol       Date:  2015-02       Impact factor: 5.315

10.  The second ESGAR consensus statement on CT colonography.

Authors:  Emanuele Neri; Steve Halligan; Mikael Hellström; Philippe Lefere; Thomas Mang; Daniele Regge; Jaap Stoker; Stuart Taylor; Andrea Laghi
Journal:  Eur Radiol       Date:  2012-09-15       Impact factor: 5.315

View more
  4 in total

1.  Predictors of Gastrointestinal Transit Times in Colon Capsule Endoscopy.

Authors:  Sarah Moen; Fanny E R Vuik; Trudy Voortman; Ernst J Kuipers; Manon C W Spaander
Journal:  Clin Transl Gastroenterol       Date:  2022-05-18       Impact factor: 4.396

2.  Deep learning in CT colonography: differentiating premalignant from benign colorectal polyps.

Authors:  Philipp Wesp; Sergio Grosu; Anno Graser; Stefan Maurus; Christian Schulz; Thomas Knösel; Matthias P Fabritius; Balthasar Schachtner; Benjamin M Yeh; Clemens C Cyran; Jens Ricke; Philipp M Kazmierczak; Michael Ingrisch
Journal:  Eur Radiol       Date:  2022-01-26       Impact factor: 7.034

Review 3.  Artificial Intelligence in Colon Capsule Endoscopy-A Systematic Review.

Authors:  Sarah Moen; Fanny E R Vuik; Ernst J Kuipers; Manon C W Spaander
Journal:  Diagnostics (Basel)       Date:  2022-08-17

Review 4.  Convolution neural network for the diagnosis of wireless capsule endoscopy: a systematic review and meta-analysis.

Authors:  Kaiwen Qin; Jianmin Li; Yuxin Fang; Yuyuan Xu; Jiahao Wu; Haonan Zhang; Haolin Li; Side Liu; Qingyuan Li
Journal:  Surg Endosc       Date:  2021-08-23       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.